# Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)

> **NCT01146119** · PHASE2 · COMPLETED · sponsor: **BiondVax Pharmaceuticals ltd.** · enrollment: 200 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Multimeric-001, 500 mcg
- **BIOLOGICAL:** Adjuvanted PBS
- **BIOLOGICAL:** PBS and TIV 15%
- **BIOLOGICAL:** PBS and TIV 50%

## Key facts

- **NCT ID:** NCT01146119
- **Lead sponsor:** BiondVax Pharmaceuticals ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-05
- **Final completion:** 2011-06
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2012-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01146119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01146119, "Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01146119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*